Abstract
Inhibition of DPP-IV enzyme has taken centre stage as a validated drug target for type 2 diabetes therapy and as a result of research efforts done towards developing effective DPP-IV inhibitors, the first clinical candidate of this class came in focus in 1998. Thus, from 1998 to 2013, these 16-years have witnessed heightened research activities in the discovery and development of clinically relevant inhibitors of DPP-IV as antidiabetic agents. The effective DPP-IV inhibitors have played a key role in this endeavour and as result there are eight approved gliptins in the clinical usage while others are in different stages of clinical trials. A wide variety of DPP-IV inhibitors were synthesized and evaluated; and were classified into several categories based on their core structural features. In this article, classification of all the clinically relevant DPP-IV inhibitors based on selectivity, clinical efficacy and safety profiles is reviewed in terms of generations. This review also encompasses clinical phase wise discussion, developmental progress, chemistry and binding modes of all clinical DPP-IV inhibitors. In addition, major challenges facing the future design and development of safe clinical DPP-IV inhibitor are also briefly mentioned.
Keywords: Binding modes, clinical trials, dipeptidyl peptidase IV (DPP-IV) generations, DPP-IV inhibitors, glucagon like peptide (GLP-1), glucose homeostasis, non-peptidomimetics, peptidomimetics, type 2 diabetes.
Current Medicinal Chemistry
Title:Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective
Volume: 21 Issue: 35
Author(s): R.N. Kushwaha, W. Haq and S.B. Katti
Affiliation:
Keywords: Binding modes, clinical trials, dipeptidyl peptidase IV (DPP-IV) generations, DPP-IV inhibitors, glucagon like peptide (GLP-1), glucose homeostasis, non-peptidomimetics, peptidomimetics, type 2 diabetes.
Abstract: Inhibition of DPP-IV enzyme has taken centre stage as a validated drug target for type 2 diabetes therapy and as a result of research efforts done towards developing effective DPP-IV inhibitors, the first clinical candidate of this class came in focus in 1998. Thus, from 1998 to 2013, these 16-years have witnessed heightened research activities in the discovery and development of clinically relevant inhibitors of DPP-IV as antidiabetic agents. The effective DPP-IV inhibitors have played a key role in this endeavour and as result there are eight approved gliptins in the clinical usage while others are in different stages of clinical trials. A wide variety of DPP-IV inhibitors were synthesized and evaluated; and were classified into several categories based on their core structural features. In this article, classification of all the clinically relevant DPP-IV inhibitors based on selectivity, clinical efficacy and safety profiles is reviewed in terms of generations. This review also encompasses clinical phase wise discussion, developmental progress, chemistry and binding modes of all clinical DPP-IV inhibitors. In addition, major challenges facing the future design and development of safe clinical DPP-IV inhibitor are also briefly mentioned.
Export Options
About this article
Cite this article as:
Kushwaha R.N., Haq W. and Katti S.B., Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective, Current Medicinal Chemistry 2014; 21 (35) . https://dx.doi.org/10.2174/0929867321666140915143309
DOI https://dx.doi.org/10.2174/0929867321666140915143309 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Anabolic Androgenic Steroids on Neuropeptide Systems
Mini-Reviews in Medicinal Chemistry Atrial Fibrillation During or After TAVI: Incidence, Implications and Therapeutical Considerations
Current Pharmaceutical Design The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Current Pharmaceutical Design Preface
Endocrine, Metabolic & Immune Disorders - Drug Targets Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Current Vascular Pharmacology Efficacy and Non Invasive Treatment of Sialorrhea in the Goldenhar Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Classification and Prediction of VIP Derivatives as VPAC1/ VPAC2 Receptor Agonists/Antagonists
Combinatorial Chemistry & High Throughput Screening Adolescent Pregnancy and Parenting
Current Psychiatry Reviews NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Screening of Antihypertensive Drugs for Osteoclastic Acid Secretion and Bone Resorption by Acridine Orange
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery*
Recent Patents on Anti-Cancer Drug Discovery Network of WNT and Other Regulatory Signaling Cascades in Pluripotent Stem Cells and Cancer Stem Cells
Current Pharmaceutical Biotechnology Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Novel Optical Techniques for Imaging Microcirculation in the Diabetic Foot
Current Pharmaceutical Design Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research A Knock-Down Cell-Based Study for the Functional Analysis of Chloride Intracellular Channel 1 (CLIC1): Integrated Proteomics and Microarray Study
Protein & Peptide Letters The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Anti-fatigue Effects of Active Ingredients from Traditional Chinese Medicine: A Review
Current Medicinal Chemistry Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews